MS
REGN icon

Maven Securities’s Regeneron Pharmaceuticals REGN Stock Holding History

Maven Securities’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-600
Closed -$527K – 856
2023
Q4 		$527K Buy
+600
New +$494K 0.01% 650
2023
Q3 		– Sell
-7,000
Closed -$5.03M – 1213
2023
Q2 		$5.03M Buy
7,000
+6,700
+2,233% +$5.17M 0.08% 129
2023
Q1 		$247K Sell
300
-1,300
-81% -$980K 0.01% 841
2022
Q4 		$1.15M Sell
1,600
-500
-24% -$369K 0.03% 394
2022
Q3 		$1.45M Buy
+2,100
New +$1.32M 0.03% 403
2021
Q4 		– Sell
-500
Closed -$303K – 1111
2021
Q3 		$303K Buy
+500
New +$310K 0.01% 828

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Maven Securities's REGN Position: Q1 2024 in Review

Maven Securities sold out of Regeneron Pharmaceuticals (REGN) in Q1 2024, closing a stake of 702 shares — an estimated $617K sold.

Maven Securities first reported a position in REGN in Q2 2020 and held it in 9 quarters. The position peaked at $772K in Q4 2020. 1,309 funds tracked by Wall St. Rank hold REGN as of Q1 2024.

  • Maven Securities reported no remaining Regeneron Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Maven Securities sold 702 Regeneron Pharmaceuticals shares in Q1 2024, an estimated $617K.
  • Maven Securities first reported a position in Regeneron Pharmaceuticals in Q2 2020 and held it in 9 quarters.
  • Maven Securities's Regeneron Pharmaceuticals position peaked at $772K in Q4 2020.
  • 1,309 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2024.

Based on Maven Securities's 13F filing for Q1 2024, filed 14 May 2024.